A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031)

Administered By

Awarded By

Contributors

Start/End

  • December 1, 2016 - April 13, 2018